Flossbach Von Storch SE purchased a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 3,923,035 shares of the conglomerate’s stock, valued at approximately $747,260,000. Danaher makes up about 3.4% of Flossbach Von Storch SE’s investment portfolio, making the stock its 10th biggest position. Flossbach Von Storch SE owned 0.56% of Danaher as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of DHR. BlackRock Inc. purchased a new stake in Danaher in the 2nd quarter worth $10,492,520,000. Norges Bank bought a new position in Danaher in the 4th quarter worth approximately $2,177,106,000. Bank of New York Mellon Corp purchased a new stake in Danaher during the 2nd quarter valued at approximately $712,875,000. Viking Global Investors LP grew its holdings in Danaher by 543.9% during the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after buying an additional 2,455,994 shares in the last quarter. Finally, Deutsche Bank AG bought a new stake in shares of Danaher during the second quarter valued at approximately $446,265,000. 79.05% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
DHR has been the subject of a number of research reports. Argus dropped their target price on shares of Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Royal Bank Of Canada lifted their price target on shares of Danaher from $200.00 to $215.00 and gave the company an “outperform” rating in a report on Wednesday, July 22nd. TD Cowen decreased their price target on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Evercore reissued an “outperform” rating and set a $230.00 price objective on shares of Danaher in a report on Monday, July 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.
Danaher Price Performance
Danaher stock opened at $211.92 on Thursday. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm’s fifty day moving average is $194.30 and its 200 day moving average is $192.44. The company has a market cap of $148.98 billion, a price-to-earnings ratio of 37.64, a PEG ratio of 2.49 and a beta of 0.78.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. During the same period last year, the company posted $0.77 EPS. The business’s revenue was up 5.5% on a year-over-year basis. Sell-side analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.
About Danaher
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Featured Stories
- Five stocks we like better than Danaher
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
